Navigation Links
Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares
Date:6/24/2013

NEW YORK, June 24, 2013 /PRNewswire/ -- Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced the completion of its previously announced underwritten public offering of 1,730,000 shares of its common stock at a public offering price of $33.01 per share.  In addition, the underwriters have exercised in full their option to purchase an additional 259,500 shares of common stock at the public offering price. 

All of the shares in the offering were sold by Intercept, with net proceeds to Intercept of approximately $61.7 million, after deducting underwriting discounts and commissions and estimated offering expenses.

BofA Merrill Lynch and Citigroup acted as joint book-running managers, BMO Capital Markets acted as lead manager and Needham & Company, Wedbush PacGrow Life Sciences and Janney Montgomery Scott acted as co-managers for the offering. 

A registration statement on Form S-1 relating to the shares of common stock sold in this offering was declared effective by the Securities and Exchange Commission on June 18, 2013.  A final prospectus relating to the offering has been filed with the SEC.  Copies of the final prospectus may be obtained from the offices of BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or via email, at dg.prospectus_requests@baml.com; or Citigroup c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone at 1-800-831-9146 or email at batprospectusdept@citi.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC) in patients with an inadequate response to, or who are unable to tolerate, ursodiol, the only approved therapy for this indication. OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has out-licensed the product candidate to Dainippon Sumitomo Pharma.


'/>"/>
SOURCE Intercept Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Piedmont Pharmaceuticals Gains FDA Approval of Animal Health Soft Chew Pain Medication
2. North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017
3. Auxilium Pharmaceuticals, Inc. To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
4. Actinium Pharmaceuticals Acute Myeloid Leukemia Clinical Data to be Presented Today at 8th International Symposium on Targeted Alpha Therapy Conference
5. Isis Pharmaceuticals Earns $10 Million Milestone Payment from AstraZeneca for ISIS-AR Rx to Treat Prostate Cancer
6. GW Pharmaceuticals plc Reports 2013 Second Quarter Financial Results
7. Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech
8. Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference
9. Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
10. Vanda Pharmaceuticals Reports First Quarter 2013 Results
11. Questcor Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Doctors in Italy, Japan, the UK and the ... associated protein (BAP1) gene and its link to malignant mesothelioma. Surviving Mesothelioma has just ... the full article now. , The studies analyzed for the new report included ...
(Date:5/27/2016)... , May 27, 2016 At present, ... playing in this space know that volatility is what makes ... companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: SNTA ... Inc. (NASDAQ: LPTN ), and Heat Biologics Inc. ... access to the technical alerts for these stocks at: ...
(Date:5/26/2016)... Jersey and READING, England ... Indegene ( http://www.indegene.com ), a leading global ... life science, pharmaceutical and healthcare organisations and TranScrip ... innovative scientific support throughout the product lifecycle, today ... the launch of IntraScience.      (Logo: ...
(Date:5/26/2016)... , May 26, 2016 Despite the ... value in this space. Today,s pre-market research on ActiveWallSt.com directs ... Health Inc. (NASDAQ: RDUS ), Cerus Corp. (NASDAQ: ... ARWR ), and Five Prime Therapeutics Inc. (NASDAQ: ... briefings at: http://www.activewallst.com/ On ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
Breaking Biology News(10 mins):